AI Insight
This study analyzed drug samples from Southern California and found that medetomidine, a potent sedative, is rapidly emerging as an adulterant in the fentanyl supply. Between May 2025 and August 2026, the prevalence of medetomidine in fentanyl samples increased from approximately 6% to 25%, with an average concentration of 0.4% by mass. All tested samples contained racemic medetomidine, indicating illicit manufacture rather than diversion from legitimate medical supplies.
Why it matters
Medetomidine is a highly potent sedative that may be replacing xylazine in the drug supply, creating significant risks for overdose and withdrawal in people who use opioids. Even at concentrations below 1.5%, medetomidine can have serious physiological effects, making this trend a critical public health concern that may require policy and harm reduction responses similar to those implemented for xylazine.
Understand the Science
⚠️ Preprint – Noch nicht peer-reviewed
Dieser Artikel wurde noch nicht von unabhängigen Experten begutachtet. Die Ergebnisse sind vorläufig und sollten mit Vorsicht interpretiert werden.
Background: Medetomidine, a potent sedative, is increasingly present in fentanyl-related hospitalizations and deaths. Multiple states have passed legislation to control xylazine, a pharmacologically similar sedative in the illicit opioid supply. Medetomidine may function as a highly potent substitute for xylazine with significant overdose risk and withdrawal potential. Medetomidine has previously been described mostly in eastern U.S. fentanyl markets. Here, we characterize medetomidine-containing drug samples obtained in Southern California 2023-2026. Methods: Anonymous participants in Southern California voluntarily provided drug products to a community-based drug checking program. All samples underwent direct-analysis-in-real-time mass spectrometry (DART-MS). A subset was quantified by liquid-chromatography tandem mass spectrometry (LC-MS/MS). A smaller subset underwent enantiomeric analysis. We calculated other compounds co-present with medetomidine, the prevalence of medetomidine in fentanyl over time, the concentration of medetomidine, and the enantiomer makeup of medetomidine. Results: The quarterly prevalence of medetomidine co-present with fentanyl rose from {approx}6 % in May 2025 (month of first detection) to {approx}25 % by August 2026. The average medetomidine concentration was 0.4 % mass fraction. The most common co-detected substances with medetomidine were fentanyl and adulterants such as lidocaine and xylazine. All medetomidine samples that underwent enantiomeric analysis (n = 13) were identified as racemic. Conclusion: Medetomidine represents a rapidly emerging adulterant in the Southern California fentanyl supply. All samples assessed for enantiomer status were racemic medetomidine, suggesting they were not diverted from human pharmaceutical or medical supplies. Given its high potency, a small amount (<1.5%) is likely still a physiologically significant quantity of the drug.
Source: Characterizing the Emergence of Medetomidine in Southern California Fentanyl Markets